N/A
Completed N=52
Tango for Neuropathy Among Breast Cancer Survivors
Cancer, Breast · neuropathy
Source: ClinicalTrials.gov NCT05114005 ↗
Enrolled (actual)
52
Serious AEs
5.8%
Results posted
Sep 2025
Primary outcomePrimary: Postural Control (Variability) — 10.3; 9.64; 8.03; 8.00 millimeters
Summary
Group dance classes have been found to improve markers of quality of life and physical health (i.e., balance) among some populations engaged in rehabilitation, such as the elderly and individuals with Parkinson Disease. However, such interventions have yet to be studied among cancer survivors despite the relevance of quality of life and physical health within cancer survivorship. Group dance classes are a promising avenue in that they deliver activity-based medicine in a social context, thus potentially improving physical as well as psychosocial aspects of health. To further this avenue of inquiry, we propose to study the effect of dance-based interventions for cancer survivors.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Postural Control (Variability) |
10.3; 9.64; 8.03; 8.00; 7.74; 8.61 | — |
| PRIMARY Intrinsic Motivation |
6; 21.5; 6; 18; 6; 16 | — |
| SECONDARY Postural Control (Ellipse Area) |
1023; 775; 595; 574; 570; 647 | — |
| SECONDARY Postural Control (Velocity) |
10.2; 12.1; 7.51; 7.92; 9.21; 8.64 | — |
| SECONDARY Postural Control (Complexity) |
0.480; 0.467; 0.558; 0.566; 0.559; 0.559 | — |
| SECONDARY Postural Control (Variability) at Tango Sessions |
8.86; 8.74 | — |
| SECONDARY Postural Control (Ellipse Area) at Tango Sessions |
749; 748 | — |
| SECONDARY Postural Control (Velocity) at Tango Sessions |
8.87; 8.08 | — |
| SECONDARY Postural Control (Complexity) at Tango Sessions |
0.520; 0.546 | — |
| SECONDARY Clinical Measure of Balance Function |
10.3; 11.7; 8.65; 8.25; 8.49; 7.70 | — |
| SECONDARY Neuropathy Symptoms Score at Tango Sessions |
6.68; 3.29 | — |
| SECONDARY Neuropathy Symptoms Score |
6.60; 6.89; 7.06; 5.18 | — |
| SECONDARY Brief Pain Inventory Short Form at Tango Sessions |
1.68; 1.20 | — |
| SECONDARY Brief Pain Inventory Short Form |
1.72; 1.07; 1.78; 1.55 | — |
| SECONDARY Cancer-Related Fatigue (BFI Scores) at Tango Sessions |
8.56; 1.21 | — |
| SECONDARY Cancer-Related Fatigue |
8.13; 10.7; 7.22; 13.3 | — |
| SECONDARY Number of Falls |
0; 1 | — |
| SECONDARY Change in Dual-task Function |
-2.65; -1.9; -2.47; -2.65; -2.68; -3.06 | — |
| SECONDARY Adherence |
26; 26; 23; 22; 20; 13 | — |
Eligibility Criteria
Inclusion Criteria
- Breast cancer survivor stage I-III
- Symptomatic for neuropathy
- postural control outside 70% CI for adults who are middle-aged without neurotrauma
- having completed taxane-based chemotherapy treatment at least 3 months ago;
- able to understand and comply with directions associated with testing and study treatments.
Exclusion Criteria
- Pre-existing vestibular deficit;
- poorly controlled diabetes (hgA1C > 8);
- non-ambulatory or lower extremity amputation (assistive devices allowed);
- use of cytotoxic or immunotherapy during study (endocrine therapy allowed);
- participation in physical therapy during the study;
- contraindication to participate in Tango due to orthopedic issue (e.g., herniated vertebral disc);
Data sourced from ClinicalTrials.gov (NCT05114005). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.